Status:
COMPLETED
Ranibizumab Plus Indomethacin
Lead Sponsor:
Università degli Studi di Brescia
Conditions:
Macular Edema
Eligibility:
All Genders
40+ years
Phase:
PHASE4
Brief Summary
To evaluate whether indomethacin eyedrops plus intravitreal ranibizumab (IVR) provides additional benefit over IVR monotherapy for treatment of choroidal neovascularization (CNV) in age-related macula...
Eligibility Criteria
Inclusion
- provision of written informed consent and compliance with study assessments for the full duration of the study
- age \> 40 years
- presence of treatment-naïve neovascular AMD.
Exclusion
- any previous intravitreal treatment
- previous laser treatment in the study eye
- myopia \> 7 diopters in the study eye
- concurrent eye disease in the study eye that could compromise visual acuity (e.g., diabetic retinopathy and advanced glaucoma)
- concurrent corneal epithelial disruption or any condition that would affect the ability of the cornea to heal
- known sensitivity to any component of the formulations being investigated.
Key Trial Info
Start Date :
January 7 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 25 2017
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT03261635
Start Date
January 7 2016
End Date
July 25 2017
Last Update
August 25 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.